Delivering nanomedicines to patients: a practical guide.
This is a perspective on the current state of development of nanomedicines in Europe. The view is expressed that a much higher translational success rate could be achieved, with rewards for all stakeholders, if researchers understood the industrial decision points required for new drugs. Getting a drug through the clinic will not help patients unless it is developable by industry. This article is written in the hope that it will help researchers and SMEs to decide where they are in the established process, whether they are making progress and to determine what to do next. It attempts to map the early stages from ideation to first (time) in man (FIM).


BACKGROUND
The field of nanomedicine has come a long way in the past decade. The overall dream of any researcher in this field remains the realization of concept to clinical product. In this paper, the authors outlined for the readers, the underlying problems and actions that need to be done, so that current challenges can be solved.
European Technology Platform on Nanomedicine - ETPN, ETPN Secretariat c/o VDI-VDE Innovation+Technik GmbH, Berlin, Germany. Electronic address: Nanomedicine@btinternet.com.
Mike A W
MA
Eaton
Nanobiotix and ETPN, Paris, France.
Laurent
L
Levy
European Technology Platform on Nanomedicine - ETPN, ETPN Secretariat c/o VDI-VDE Innovation+Technik GmbH, Berlin, Germany.
Olivier M A
OM
Fontaine
D003695:Delivery of Health Care / Q000379:methods* / Q000639:trends*; D005060:Europe; D006801:Humans; D050997:Nanomedicine / Q000379:methods* / Q000639:trends*
Commercialize; Development; Milestones; TRL; Translation